Aro Bio Bolsters Board with Valo Health COO Brett Blackman
Aro Biotherapeutics, a clinical-stage biotech developing targeted siRNA medicines, has appointed Brett Blackman, Ph.D., to its Board of Directors. Blackman currently serves as Senior Vice President, Chief Operating Officer, and Chief Business Officer at Valo Health, bringing over 25 years of experience in drug discovery, engineering, and business strategy.
PHILADELPHIA, Sept. 29, 2026 — Aro Biotherapeutics, a clinical-stage biotechnology company focused on targeted short-interfering RNA (siRNA) medicines, announced today the appointment of Brett Blackman, Ph.D., to its Board of Directors. Blackman currently serves as Senior Vice President, Chief Operating Officer, and Chief Business Officer at Valo Health, where he oversees corporate operations, strategy, business development, alliance management, portfolio program management, and legal affairs.
Blackman brings more than 25 years of experience spanning drug discovery, engineering, and business strategy, a combination that Aro Biotherapeutics believes will strengthen its strategic direction as it advances its pipeline of siRNA therapies for diseases with high unmet medical need. His dual fluency in science and corporate strategy is expected to be particularly valuable as the company navigates clinical development and potential partnerships.
The appointment signals Aro Biotherapeutics' intent to bolster its leadership with seasoned industry expertise. As the company continues to develop targeted siRNA medicines, Blackman's operational and business development insights could play a key role in shaping its growth trajectory and future collaborations. The move is effective immediately, and no further board changes were announced.
Comments (0)
No comments yet. Be the first to share your thoughts!
Leave a Comment